Fredun Pharmaceuticals: Revised Outcome of Board Meeting Dated 0 3rd October, 2026 Re: Allotment of 1,82,400 Equity Shares to Non -…

What happened

Fredun Pharmaceuticals (FREDUN) filed a disclosure with the exchanges on 5 October 2026 at 08:20 PM titled "Revised Outcome of Board Meeting Dated 0 3rd October, 2026 Re: Allotment of 1,82,400 Equity Shares to Non - Promoter Allottees".

Company snapshot

Fredun Pharmaceuticals is a small-cap company, with a market value of about ₹2,254 crore.

The stock last traded at ₹1,363.2, against a 52-week range of ₹1,195.2–₹1,590 (14.3% below the high).

Before this filing the shares had moved −9.5% over the month. Average daily turnover over the last 20 sessions was about ₹9.66 crore.

Promoters held 44.57% at the end of Q2 FY27. Foreign institutions owned 1.06% and domestic institutions 2.94%.

What history shows

BCEIE's records show 3 previous board meeting filings from the company since May 2026.

Market-wide, 2,856 board meeting filings with an impact score of 50 or more saw an average next-day move of −0.0%, with 43% rising.

Past reactions describe what happened before; they are not a forecast.

In the news

Recent coverage elsewhere (links open the original publisher):

• Fredun Pharmaceuticals acquires 26% stake in Rs. 300 crore valued Goodman Vetcare — Indian Pharma Post, 22 Sept 2026
• Fredun Pharmaceuticals Acquires 26% Stake in Goodman Vetcare — Machine Maker, 25 Sept 2026
• Fredun buys 26% of Goodman Vetcare, valuing pet-care chain at ₹300 crore — Dealroom, 23 Sept 2026
• Fredun Pharmaceuticals acquires 26 per cent stake in Goodman Vetcare — ETRetail.com, 22 Sept 2026
• Fredun Pharma acquires 26% stake in Goodman Vetcare Private Limited — TradingView, 22 Sept 2026

Source

• Exchange filing (PDF)